E-mail a Wiley Online Library Link

Yehuda Z. Patt, Manal M. Hassan, Richard D. Lozano, Ajay K. Nooka, Isaac I. Schnirer, Jerome B. Zeldis, James L. Abbruzzese and Thomas D. Brown Thalidomide in the treatment of patients with hepatocellular carcinoma Cancer 103

Version of Record online: 19 JAN 2005 | DOI: 10.1002/cncr.20821

In a Phase II trial, the authors assessed the antitumor activity, treatment tolerance, treatment-related toxicity, and patient survival after thalidomide was administered to cirrhotic patients with hepatocellular carcinoma (HCC). Because of significant neurologic toxicity, mostly drowsiness, thalidomide monotherapy at the high doses studied cannot be recommended for the treatment of HCC.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field